Aslan Fred sold $422K of ARTV

Artiva Biotherapeutics (ARTV) halts AlloNK development after two patient deaths and negative clinical data. The company is evaluating strategic options, including a sale or liquidation, and cutting 94% of its workforce. ARTV reported $319.1M in cash as of September 30, 2026, but no assurance of a transaction outcome.

Artiva Biotherapeutics (ARTV) halts AlloNK development after updated data showed insufficient durability and recent Grade 5 events. The company will cut 94% of its workforce and explore strategic options, including a sale or liquidation. As of September 30, 2026, it had approximately $319.1 million in cash and investments (unaudited).

Artiva Biotherapeutics (ARTV) is halting development of AlloNK® (AB-101) due to safety concerns and insufficient long-term efficacy data. The company will cut 94% of its workforce and explore strategic alternatives, including potential mergers or liquidation. Artiva had $319.1M in cash as of September 30, 2026.

H.C. Wainwright reiterated a Buy rating and $35 price target on Artiva Biotherapeutics (ARTV). The stock has risen 130% in the past year, trading at $6.79. Analysts cite undervaluation and positive clinical data for Sjögren’s disease treatment. The firm sees potential for rheumatoid arthritis trial success in 2026.

Cantor Fitzgerald maintained an Overweight rating and $40 price target for Artiva Biotherapeutics, implying a 489.1% upside from the Oct 1 close. The firm cited strong early efficacy data and a favorable safety profile for Artiva's AlloNK therapy, which showed improvements in symptoms and lacked severe adverse events.

Artiva Biotherapeutics (ARTV) presented six-month clinical data for AlloNK therapy in Sjögren disease patients, showing improvements in disease activity and symptoms. The study included 11 patients, with no serious safety concerns reported. The company plans a Phase 3 trial for rheumatoid arthritis in late 2026.